Salarius Pharmaceuticals Inc. logo

Salarius Pharmaceuticals Inc. (SLRX)

Market Closed
13 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 66
-0.05
-7.07%
$
1.4M Market Cap
- P/E Ratio
0% Div Yield
67,500 Volume
-5.32 Eps
$ 0.71
Previous Close
Day Range
0.61 0.7
Year Range
0.45 7.2

Summary

SLRX closed yesterday lower at $0.66, a decrease of 7.07% from Thursday's close, completing a monthly decrease of -13.67% or $0.1. Over the past 12 months, SLRX stock lost -63.09%.
SLRX is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, missed the consensus estimates by -1.02%. On average, the company has surpassed earnings expectations by 17.27%, based on the last three reports.
Salarius Pharmaceuticals Inc. has completed 3 stock splits, with the recent split occurring on Jun 17, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track SLRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

SLRX Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer

Globenewswire | 2 months ago
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990.

Globenewswire | 4 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRX

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRX

NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Salarius Pharmaceuticals, Inc. ( Nasdaq : SLRX ), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.

Globenewswire | 5 months ago

Salarius Pharmaceuticals Inc. Dividends

SLRX is not paying dividends to its shareholders.

Salarius Pharmaceuticals Inc. Earnings

12 May 2025 Date
-
Cons. EPS
-
EPS
20 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Aug 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS
SLRX is not paying dividends to its shareholders.
12 May 2025 Date
-
Cons. EPS
-
EPS
20 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Aug 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS

Salarius Pharmaceuticals Inc. (SLRX) FAQ

What is the stock price today?

The current price is $0.66.

On which exchange is it traded?

Salarius Pharmaceuticals Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is SLRX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.4M.

Has Salarius Pharmaceuticals Inc. ever had a stock split?

Salarius Pharmaceuticals Inc. had 3 splits and the recent split was on Jun 17, 2024.

Salarius Pharmaceuticals Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. David J. Arthur M.B.A. CEO
NASDAQ (CM) Exchange
79400X404 Cusip
US Country
2 Employees
- Last Dividend
17 Jun 2024 Last Split
29 Jan 2015 IPO Date

Overview

Salarius Pharmaceuticals, Inc. is a trailblazing clinical-stage biotechnology firm devoted to the innovation of treatments for cancers that lack sufficient medical solutions. Positioned at the forefront of cancer research, the company's dynamism is rooted in its relentless pursuit to address and fulfill unmet medical needs through groundbreaking research and development. Salarius is distinguished by its strategic partnerships, one with The University of Utah Research Foundation, granting it exclusive rights to crucial patent protections for its leading compound and related chemicals, and another significant collaboration with the Cancer Prevention and Research Institute of Texas, which supports its product development initiatives. Operating from its headquarters in Houston, Texas, Salarius Pharmaceuticals, Inc. embodies a beacon of hope in the ongoing battle against cancer, demonstrating a steadfast commitment to advancing oncological care through scientific innovation and strategic alliances.

Products and Services

  • Seclidemstat (SP-2577)

This pioneering compound serves as Salarius Pharmaceuticals' flagship candidate, exemplifying the company's dedication to cancer research. Positioned in the critical Phase I/II clinical trial stage, Seclidemstat targets advanced solid tumors and Ewing sarcoma. Its mechanism as a small molecular inhibitor sets a precedent in the therapeutic landscape, offering a novel approach to combat these formidable cancers. The promise of Seclidemstat extends beyond its current trial phase, highlighting Salarius's commitment to addressing and overcoming challenges in oncology.

  • SP-3164

Expanding its arsenal in the fight against cancer, Salarius introduces SP-3164, a sophisticated small molecular protein degrader. This formidable agent is designated for the treatment of both hematological malignancies and solid tumors, showcasing the company's versatile approach to cancer therapy. SP-3164 represents Salarius’s endeavor to diversify its therapeutic portfolio, aiming at broader targets in the oncology spectrum and underscoring its innovative spirit and relentless pursuit of cancer eradication.

Contact Information

Address: 2450 Holcombe Boulevard
Phone: 832 834 6992